Koki Abe

Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats

H Oshima, Takayuki Miki, Atsushi Kuno et al. · Journal of Pharmacology and Experimental Therapeutics · 2018 · 119 citations · Full text

Development of the Human Umbilical Vein Scaffold for Cardiovascular Tissue Engineering Applications

Joel Daniel, Koki Abe, Peter S. McFetridge · ASAIO Journal · 2005 · 87 citations

Tissue Engineering, Engineering, Biomaterials Design +22

mTORC1 inhibition attenuates necroptosis through RIP1 inhibition-mediated TFEB activation

Koki Abe, Toshiyuki Yano, Masaya Tanno et al. · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2019 · 77 citations · Full text

Mitophagy, Apoptosis, Immunology +17

Canagliflozin, a sodium–glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats

Yukishige Kimura, Atsushi Kuno, Masaya Tanno et al. · Journal of Diabetes Investigation · 2019 · 57 citations · Full text

Suppression of autophagic flux contributes to cardiomyocyte death by activation of necroptotic pathways

Makoto Ogasawara, Toshiyuki Yano, Masaya Tanno et al. · Journal of Molecular and Cellular Cardiology · 2017 · 45 citations

Cardiac Muscle, Mitophagy, Heart Failure +16